17 Aug Lamotrigine – Risk of Hemophagocytic Lymphohistiocytosis
Posted at 13:03h
in
In agreement with the South African Health Products Regulatory Authority (SAHPRA), Aurobindo Pharma (Pty) Ltd would like to inform you of the following important information regarding the risk of Hemophagocytic Lymphohistiocytosis (HLH) associated with the use of lamotrigine containing medicines.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
17/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals